-transparent.png){kind=logo}
In 44 ovarian cancers, CD44 variant (CD44v) expression was investigated immunohistochemically using a variant-specific polyclonal antibody. Patients with CD44v-positive carcinomas had a significantly shorter disease-free survival than patients with CD44v-negative tumors. Overall survival was also significantly reduced for stages III and IV of the International Federation of Gynecology and Obstetrics. Furthermore, a highly significant inverse correlation was observed between CD44v expression and preoperative platelet count. Urinary neopterin concentration, a marker of cell-mediated immunostimulation, did not differ between CD44v-positive and -negative ovarian cancer patients. Moreover, in seven ovarian carcinoma cell lines, modulation of CD44v expression was analyzed by living cell radioimmunoassay. Interferon-alpha, interferon-gamma, tumor necrosis factor, transforming growth factor-beta, all-trans retinoic acid and cisplatin did not affect CD44v expression.
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
January 2001,
Oncology reports,
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
June 1999,
International journal of cancer,
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
January 1997,
Anticancer research,
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
September 1995,
European journal of cancer (Oxford, England : 1990),
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
January 2016,
PloS one,
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
January 2001,
Histopathology,
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
November 2016,
Archives of gynecology and obstetrics,
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
February 2001,
European urology,
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
April 1998,
British journal of cancer,
M Uhl-Steidl, and
E Müller-Holzner, and
A G Zeimet, and
G R Adolf, and
G Daxenbichler, and
C Marth, and
O Dapunt
January 2014,
Asian Pacific journal of cancer prevention : APJCP,
